Roche’s Acquisition of Genentech Harvard Case Solution & Analysis

Roche’s Acquisition of Genentech Case Study Solution 

Offering 44% Equity

Holding the 100% of equity shares for a short duration, after working out the alternative in 1999, Roche sold about 44% of its equity shares in the market. The 19% of the shares were initially sold to the public, for which the business planned to relist the business under new ticker. Roche than used even more 20 million shares that were cumulatively about 15.6% of the shares of Genentech.

Apart from this, the business has also released options to the staff members of the business who might buy the equity shares of the company. With the increasing success of the company over the past years and very worthwhile potential customers the employees of the company began exercising the share choices which left Roche with only 56 % of the share, while staying 44% were offered in the percentages discussed above.


The benefit that Roche received, as an outcome of selling out the part of its 100% ownership of Genentech is that, the subsidiary company that went through current violation suit with the University of California. The business was able to safeguard itself from the heavy effects of the suit, the business still experienced some bad publicity that may have affected the future credibility of the company. For this factor, the business sold 44% of the shares to the marketplace which resulted in increased share rate of the subsidiary business.

Roche’s Acquisition of Genentech Harvard Case Solution & Analysis

On other hand, thinking about the advantage moms and dad (Roche) have actually gotten from offering out the shares which can be depicted as the moms and dad company had taken an action to enhance the success and the market price of its subsidiary that will increase the worth of its existing shareholdings. This gave the moms and dad rights over the subsidiary in terms of approval rights for any decisions of worth above 5% of the equity shares and right to acquire majority representation on the board of Genentech by appointing new directors.

Question 2

In order to figure out the worth of Genentech, numerous valuation models can be used that will approximate the worth of the company from various point of views. In this regard, the value of the company has been estimated in terms of the per share cost of the business. The two techniques utilized are discounted capital strategy and the similar business analysis, as shown in the Excel sheets.

Affordable Cash Flow Valuation

The Reduced Capital (DCF) evaluation of Genentech is based on assumptions of the growth rate and the percentage of the expenses and expenditures as a portion of sales as offered in Exhibition 13. These assumptions and percentages have been mentioned in the excel sheet too.

Continuing with the valuation of the business, the revenues have been forecasted for the years after 2008 until 2018 with the development rate of 7% as given up Exhibit 13. The other components of the costs and expenditures that are based on the portion of these revenues are then calculated. Lastly, the free cash flows have been calculated for each year of operation.

The present worth of the terminal worth of totally free money flows after the year 2018 at a growth rate of 2% for the foreseeable future. Including the excess money the total value of the business is calculated to be $79,695 million with the total number of outstanding shares of 1053 million.

Similar Business Analysis

Alternatively, a various approach of valuation through multiples of various comparable business of Genentech has been carried out, under the equivalent business analysis. The variety of values per share of the company has actually been determined from this analysis that will be discussed in turn.

The price earnings multiple of the equivalent companies for the 2 years have been drawn out from the Exhibit 13 in terms of industry mean and mean. The value per share of the Genentech is then computed by multiplying the revenues per share of the company with the typical PE multiple.

Different values on the basis of entire industry, core similar, and the real PE of Genentech have been estimated. The most reasonable value of the per share might be portrayed as determined through industry mean that is better the DCF worth per share, along with the worth per share based upon actual PE of Genentech.

Secondly, the EBITDA to earnings multiple of the comparable business for the 2 years have actually been drawn out from the Exhibition 13 in terms of market mean and average along with core comparable business. The value per share of the Genentech is then computed by multiplying the EBITDA of the company with the typical EBITDA/Revenue multiple.

From the appraisal through this multiple, the realistic value of the business can be illustrated as the worth under the median of industry similar i.e. $72.67. Whereas, from the actual multiple of the Genentech the value approximated is $ 90.68 which is considerably higher.

First of all, the enterprise worth to income multiple of the equivalent business for the 2 years have actually been extracted from the Exhibition 13 in terms of market mean and average as well as the core equivalent companies. The worth per share of the Genentech is then calculated by increasing the profits of the business with the average Enterprise Value/Revenue several.

Various worth’s on the basis of whole industry, core similar, and the actual PE of Genentech have actually been estimated. The most reasonable value per share could be illustrated as computed through market mean i.e. $71.36 per share which is closer the DCF value per share. The worth per share on the basis of actual numerous is determined as $82.83 which is greater than the comparable or DCF evaluation................

This is just a sample partial case solution. Please place the order on the website to order your own originally done case solution.

Share This


Save Up To




Register now and save up to 30%.